Through a compendium of TF binding signatures and paired variations in chromatin accessibility and gene expression, we predict human pioneer and regulatory transcription factors that prime all relevant genes for transcriptional activation and repression across three stages of hiPSC-derived RPE differentiation and related regulatory elements with pharmacogenomic potential for treatment of AMD and RPE degenerative conditions. This evidence concerns the gene TF and age-related macular degeneration.